J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
INR 1934.75
(4.25%)
INR 1934.75
(4.25%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.77 Billion INR | -34.03% |
| 2022 | 5.72 Billion INR | 949.23% |
| 2021 | 545.58 Million INR | 21.27% |
| 2020 | 449.87 Million INR | 17.71% |
| 2019 | 382.18 Million INR | 48.15% |
| 2018 | 257.97 Million INR | -11.93% |
| 2017 | 292.92 Million INR | -40.05% |
| 2016 | 488.6 Million INR | -74.69% |
| 2015 | 1.93 Billion INR | 52.45% |
| 2014 | 1.26 Billion INR | 55.39% |
| 2013 | 814.81 Million INR | 119.66% |
| 2012 | 370.94 Million INR | -45.27% |
| 2011 | 677.71 Million INR | -59.91% |
| 2010 | 1.69 Billion INR | 23.62% |
| 2009 | 1.36 Billion INR | -23.5% |
| 2008 | 1.78 Billion INR | -8.96% |
| 2007 | 1.96 Billion INR | 12.61% |
| 2006 | 1.74 Billion INR | 82.34% |
| 2005 | 956.25 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 3.77 Billion INR | -34.03% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 4.5 Billion INR | 0.0% |
| 2023 Q4 | 3.77 Billion INR | 0.0% |
| 2022 Q4 | 5.72 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 3.74 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 5.72 Billion INR | 949.23% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 545.58 Million INR | 21.27% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 545.58 Million INR | 0.0% |
| 2021 Q2 | 554.68 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 305.69 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 449.87 Million INR | 17.71% |
| 2020 Q4 | 449.87 Million INR | 0.0% |
| 2019 Q4 | 382.18 Million INR | 0.0% |
| 2019 Q2 | 471.13 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 382.18 Million INR | 48.15% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 257.97 Million INR | -11.93% |
| 2018 Q4 | 257.97 Million INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 292.92 Million INR | -40.05% |
| 2016 Q4 | 488.6 Million INR | 0.0% |
| 2016 FY | 488.6 Million INR | -74.69% |
| 2015 FY | 1.93 Billion INR | 52.45% |
| 2015 Q4 | 1.93 Billion INR | 0.0% |
| 2014 FY | 1.26 Billion INR | 55.39% |
| 2013 FY | 814.81 Million INR | 119.66% |
| 2012 FY | 370.94 Million INR | -45.27% |
| 2011 FY | 677.71 Million INR | -59.91% |
| 2010 FY | 1.69 Billion INR | 23.62% |
| 2009 FY | 1.36 Billion INR | -23.5% |
| 2008 FY | 1.78 Billion INR | -8.96% |
| 2007 FY | 1.96 Billion INR | 12.61% |
| 2006 FY | 1.74 Billion INR | 82.34% |
| 2005 FY | 956.25 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | -164.002% |
| Ind-Swift Limited | 10.13 Billion INR | 62.755% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -13.471% |
| Sakar Healthcare Limited | 793.51 Million INR | -375.932% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 94.319% |
| Innova Captab Limited | 2.45 Billion INR | -54.082% |
| Divi's Laboratories Limited | 30 Million INR | -12488.667% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -8113.214% |
| Morepen Laboratories Limited | 289.99 Million INR | -1202.312% |
| Mankind Pharma Limited | 2.07 Billion INR | -82.293% |
| Sequent Scientific Limited | 4.87 Billion INR | 22.562% |
| Wanbury Limited | 1.16 Billion INR | -224.215% |
| Laurus Labs Limited | 25.77 Billion INR | 85.347% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 40.576% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -2102.356% |
| Alembic Limited | 91.5 Million INR | -4027.432% |
| Hikal Limited | 8.17 Billion INR | 53.808% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 26.405% |
| Neuland Laboratories Limited | 953.89 Million INR | -295.913% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 69.319% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -1052.808% |
| Themis Medicare Limited | 957.92 Million INR | -294.249% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 53.039% |
| Lupin Limited | 29.21 Billion INR | 87.074% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -21751.53% |
| Wockhardt Limited | 23.56 Billion INR | 83.97% |
| Vaishali Pharma Limited | 134.91 Million INR | -2699.182% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -32.396% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -4123.912% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 89.693% |
| FDC Limited | 205.18 Million INR | -1740.583% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 81.136% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -1093.371% |
| Eris Lifesciences Limited | 27.81 Billion INR | 86.421% |
| Venus Remedies Limited | 413.3 Million INR | -813.767% |
| ZIM Laboratories Limited | 1.08 Billion INR | -247.036% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -278.265% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -19070.558% |
| Shilpa Medicare Limited | 9.37 Billion INR | 59.711% |
| Albert David Limited | 33.24 Million INR | -11260.929% |
| Ajanta Pharma Limited | 352.8 Million INR | -970.465% |
| Hester Biosciences Limited | 2.44 Billion INR | -54.539% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -481.048% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 62.663% |
| Gufic Biosciences Limited | 3.32 Billion INR | -13.44% |
| Windlas Biotech Limited | 36.41 Million INR | -10272.425% |
| Procter & Gamble Health Limited | 95.6 Million INR | -3850.418% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -1104.568% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -283.44% |
| Granules India Limited | 13.15 Billion INR | 71.282% |
| Aarti Drugs Limited | 5.64 Billion INR | 33.071% |
| Bal Pharma Limited | 1.39 Billion INR | -170.436% |
| Alkem Laboratories Limited | 14.18 Billion INR | 73.374% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 88.464% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -35301.2% |
| Medicamen Biotech Limited | 308.17 Million INR | -1125.484% |
| Unichem Laboratories Limited | 2.47 Billion INR | -52.581% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -1448.466% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -85946.936% |
| Valiant Laboratories Limited | 767.08 Million INR | -392.332% |
| Orchid Pharma Limited | 1.35 Billion INR | -179.374% |
| Medico Remedies Limited | 80.5 Million INR | -4591.195% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -2172.104% |
| Ipca Laboratories Limited | 14.38 Billion INR | 73.744% |
| Brooks Laboratories Limited | 56.41 Million INR | -6593.844% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -421.007% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.295% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 90.61% |
| NATCO Pharma Limited | 3.71 Billion INR | -1.74% |
| Suven Life Sciences Limited | 7.09 Million INR | -53114.034% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -95.244% |
| Strides Pharma Science Limited | 25.16 Billion INR | 84.995% |
| Indoco Remedies Limited | 6.71 Billion INR | 43.797% |
| Alpa Laboratories Limited | 52.46 Million INR | -7098.323% |
| Lasa Supergenerics Limited | 220.76 Million INR | -1610.711% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -517.596% |